AJANTA PHARMA | PIRAMAL ENTERPRISES | AJANTA PHARMA/ PIRAMAL ENTERPRISES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 27.1 | -37.8 | - | View Chart |
P/BV | x | 6.7 | 1.3 | 525.6% | View Chart |
Dividend Yield | % | 0.5 | 1.8 | 28.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AJANTA PHARMA Mar-19 |
PIRAMAL ENTERPRISES Mar-19 |
AJANTA PHARMA/ PIRAMAL ENTERPRISES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,422 | 3,303 | 43.1% | |
Low | Rs | 898 | 1,797 | 50.0% | |
Sales per share (Unadj.) | Rs | 233.5 | 716.5 | 32.6% | |
Earnings per share (Unadj.) | Rs | 44.0 | 79.7 | 55.2% | |
Cash flow per share (Unadj.) | Rs | 52.2 | 107.9 | 48.3% | |
Dividends per share (Unadj.) | Rs | 9.00 | 28.00 | 32.1% | |
Dividend yield (eoy) | % | 0.8 | 1.1 | 70.7% | |
Book value per share (Unadj.) | Rs | 255.1 | 1,477.5 | 17.3% | |
Shares outstanding (eoy) | m | 88.02 | 184.45 | 47.7% | |
Bonus/Rights/Conversions | BB | IS | - | ||
Price / Sales ratio | x | 5.0 | 3.6 | 139.6% | |
Avg P/E ratio | x | 26.4 | 32.0 | 82.5% | |
P/CF ratio (eoy) | x | 22.2 | 23.6 | 94.1% | |
Price / Book Value ratio | x | 4.5 | 1.7 | 263.5% | |
Dividend payout | % | 20.5 | 35.1 | 58.3% | |
Avg Mkt Cap | Rs m | 102,081 | 470,292 | 21.7% | |
No. of employees | `000 | 6.8 | 7.8 | 87.0% | |
Total wages/salary | Rs m | 4,307 | 22,504 | 19.1% | |
Avg. sales/employee | Rs Th | 3,022.6 | 16,899.4 | 17.9% | |
Avg. wages/employee | Rs Th | 633.4 | 2,877.7 | 22.0% | |
Avg. net profit/employee | Rs Th | 569.1 | 1,879.9 | 30.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 20,554 | 132,153 | 15.6% | |
Other income | Rs m | 211 | 3,128 | 6.7% | |
Total revenues | Rs m | 20,765 | 135,281 | 15.3% | |
Gross profit | Rs m | 5,664 | 66,290 | 8.5% | |
Depreciation | Rs m | 721 | 5,202 | 13.9% | |
Interest | Rs m | 12 | 44,097 | 0.0% | |
Profit before tax | Rs m | 5,143 | 20,119 | 25.6% | |
Minority Interest | Rs m | 0 | 3,194 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,273 | 8,611 | 14.8% | |
Profit after tax | Rs m | 3,870 | 14,701 | 26.3% | |
Gross profit margin | % | 27.6 | 50.2 | 54.9% | |
Effective tax rate | % | 24.8 | 42.8 | 57.8% | |
Net profit margin | % | 18.8 | 11.1 | 169.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,812 | 122,742 | 9.6% | |
Current liabilities | Rs m | 3,776 | 310,810 | 1.2% | |
Net working cap to sales | % | 39.1 | -142.3 | -27.5% | |
Current ratio | x | 3.1 | 0.4 | 792.1% | |
Inventory Days | Days | 77 | 23 | 335.5% | |
Debtors Days | Days | 82 | 39 | 210.1% | |
Net fixed assets | Rs m | 14,398 | 116,904 | 12.3% | |
Share capital | Rs m | 175 | 369 | 47.5% | |
"Free" reserves | Rs m | 22,277 | 272,161 | 8.2% | |
Net worth | Rs m | 22,452 | 272,530 | 8.2% | |
Long term debt | Rs m | 7 | 270,196 | 0.0% | |
Total assets | Rs m | 26,962 | 856,261 | 3.1% | |
Interest coverage | x | 444.3 | 1.5 | 30,512.7% | |
Debt to equity ratio | x | 0 | 1.0 | 0.0% | |
Sales to assets ratio | x | 0.8 | 0.2 | 493.9% | |
Return on assets | % | 14.4 | 6.9 | 209.6% | |
Return on equity | % | 17.2 | 5.4 | 319.5% | |
Return on capital | % | 23.0 | 12.4 | 184.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 10,682 | 15,200 | 70.3% | |
Fx outflow | Rs m | 2,102 | 4,889 | 43.0% | |
Net fx | Rs m | 8,580 | 10,312 | 83.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,748 | -115,975 | -3.2% | |
From Investments | Rs m | -2,228 | -8,265 | 27.0% | |
From Financial Activity | Rs m | -1,475 | 107,525 | -1.4% | |
Net Cashflow | Rs m | 45 | -16,650 | -0.3% |
Indian Promoters | % | 73.8 | 52.9 | 139.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 1.6 | 4.0 | 38.8% | |
FIIs | % | 7.6 | 26.6 | 28.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.0 | 16.5 | 103.0% | |
Shareholders | 20,968 | 93,274 | 22.5% | ||
Pledged promoter(s) holding | % | 4.4 | 0.0 | - |
Compare AJANTA PHARMA With: BIOCON WOCKHARDT VENUS REMEDIES DR. DATSONS LABS GLENMARK PHARMA
Compare AJANTA PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
The SGX Nifty opened on a positive note today. At 8:10 am, it was trading up by 126 points, or 0.87% higher at 14,480 levels.
For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
More